BOULDER, Colo., Sept. 11, 2015 /PRNewswire/ -- Array
BioPharma Inc. (NASDAQ: ARRY) today announced presentations on
encorafenib and binimetinib at the 2015 European Cancer Congress
(ECC), which will be held September 25 - 29,
2015 in Vienna,
Austria. These products are currently advancing in a total of
three pivotal trials, with top-line results expected over the next
year from the NEMO (binimetinib monotherapy in NRAS mutant
melanoma) and COLUMBUS (binimetinib and encorafenib in BRAF mutant
melanoma) Phase 3 trials.
Ron Squarer, Chief Executive Officer of Array, noted, "We are
encouraged to see two ECC abstracts reporting clinical data from
binimetinib and encorafenib. Importantly, the LOGIC2
presentation at ECC will provide a further opportunity to
demonstrate the safety and clinical activity profile of this
combination in a larger, independent data set."
The following is a summary of the presentations that will be
given at ECC.
ORAL PRESENTATION
|
Title:
|
A phase 1b/2
study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with
binimetinib (MEK162; MEK inhibitor) in patients with
NRAS-mutant melanoma naive to BRAFi treatment (Abstract
#3300)
|
|
Presenter:
|
Carla van Herpen,
MD
|
|
Date:
|
Monday, September 28,
9 – 9:15 a.m. CEST (Oral Presentation)
|
|
Updated data
will be provided at the conference, beyond what is included in the
abstract.
|
POSTER PRESENTATION WITH SPOTLIGHT SESSION
|
Title:
|
LOGIC2: Phase 2,
multi-center, open-label study of sequential
encorafenib/binimetinib combination followed by a rational
combination with targeted agents after progression, to overcome
resistance in adult patients with locally-advanced or metastatic
BRAF V600 melanoma (Abstract #3310)
|
|
Presenter:
|
Reinhard Dummer,
MD
|
|
Date:
|
Sunday, September 27,
4:45 - 6:45 p.m. CEST
|
|
Abstract #3310
will also be included in the Poster Spotlight Session on Sunday,
September 27, 5:15 - 6:15 p.m.
|
|
Updated data
will be provided at the conference, beyond what is included in the
abstract.
|
All abstracts can be accessed through the ECC website,
http://www.esmo.org/Conferences/European-Cancer-Congress-2015.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Six registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 /
wholly-owned) and selumetinib (AstraZeneca). For more information
on Array, please go to www.arraybiopharma.com.
|
CONTACT:
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-announces-clinical-data-presentations-at-the-2015-european-cancer-congress-300141452.html
SOURCE Array BioPharma